Patra NeurosurgicalPatient education

Condition

Brain arteriovenous malformation (AVM)

A tangle of abnormal blood vessels in the brain where arteries connect straight to veins. It can bleed or cause seizures. Choices range from watching it to removing or closing it, and they differ for AVMs that have bled and those that have not.

How this page was written
Compiled from the sources cited on the page, with AI drafting assistance
Clinical review
Not individually reviewed by a clinician. How pages are written
Last updated
November 17, 2026

General information, not medical advice. In an emergency call 911. Full disclaimer

What it is

Normally, blood flows from arteries through tiny vessels called capillaries and then into veins. In an arteriovenous malformation (AVM), a tangle of abnormal vessels lets arteries drain straight into veins. [1] Most brain AVMs are present from birth. [3]

An AVM is called ruptured if it has bled and unruptured if it has not. This difference shapes almost every decision.

Symptoms

About half of people learn they have an AVM because it bleeds. Others learn of it from a scan done for another reason. [1] Symptoms can include:

How it is diagnosed

MRI shows the AVM and the brain around it. A catheter angiogram, which uses dye and X-rays, gives the most detailed picture of the vessels. A CT scan is useful to look for bleeding. [3] Repeat scans may be needed to check for growth or new bleeding. [1]

Spetzler-Martin grade. Doctors grade AVMs from I to V to estimate the risk of surgery. The grade adds up 3 things: how big the AVM is, whether it sits in or next to brain that controls key functions such as movement or language, and whether it drains into deep veins. A higher grade means higher surgical risk. [1] Grades I and II are often grouped together as lower risk. Grades IV and V are grouped as highest risk. [4]

How it changes over time

Unruptured AVMs. A review of 9 studies of 3923 people found a bleeding risk of about 2 out of 100 per year. [5] Other studies have found about 1 out of 100 per year. [1]

Ruptured AVMs. The risk is higher, about 4 to 5 out of 100 per year. [5] It is highest in the first year after a bleed, about 6 to 8 out of 100, and then falls. [1]

Bleeding risk is also higher when the AVM is deep in the brain, drains only into deep veins, or has a bulging weak spot (aneurysm) nearby. [5] Pregnancy can raise the chance of a serious bleed. [3]

Treatment choices

Watching (medical management). Medicine treats seizures or headaches, and scans are repeated over time. The AVM can still bleed. [1] [3]

Microsurgery. A surgeon removes the AVM right away through an opening in the skull. [1] [6] It works best for small AVMs near the surface. [3] See microsurgical removal of a brain AVM.

Radiosurgery. Focused radiation slowly damages the AVM vessels until they close. The AVM can still bleed until it closes. [3] In lower-grade AVMs, closure was seen about 2 years after treatment. [7]

Embolization. A catheter is passed through the blood vessels into the AVM to fill it with material that blocks blood flow. It rarely closes the AVM on its own, so it is often combined with surgery or radiosurgery. [3]

How often each treatment closed the AVM. A review of 137 studies found complete closure in about 96 out of 100 people after microsurgery, 38 out of 100 after radiosurgery, and 13 out of 100 after embolization. Complications causing lasting harm or death happened in about 5 to 7 out of 100 with each method. [8]

By grade. One approach suggests surgery for grades I and II, combined treatment for grade III, and watching for grades IV and V unless the AVM bleeds again or symptoms keep getting worse. [4]

If the AVM has bled

The higher risk of another bleed is part of what the team weighs. [1] The ARUBA trial described below did not include people whose AVM had bled, so its results do not apply to them. [9]

If the AVM has not bled: the ARUBA trial

ARUBA randomly assigned 226 adults with an unruptured AVM to medicine alone or to medicine plus treatment to remove or close the AVM. [10]

Limits and criticisms. The trial stopped early. Only 18 of 114 people in the treatment group had surgery, and many were still in treatment when results were reported. It was not designed to compare surgery, radiosurgery, and embolization with each other. [9] Critics point to its short follow-up and possible bias in who joined. [1] The trial authors respond that its patients had smaller, lower-grade AVMs than in the general population, which should favor treatment. [9] A US registry of 173 treated people who would have qualified for ARUBA found death or stroke in about 9 out of 100, but it was not randomized and follow-up was shorter. [11] In a review of unruptured AVMs, surgery for grades I and II closed about 99 out of 100. Watching seemed reasonable for higher grades without high-risk features. [12]

Questions to ask

  1. Has my AVM bled, and how does that change my risk?
  2. What is its Spetzler-Martin grade, and what features raise my risk?
  3. What are my yearly chances of a bleed if we watch it?
  4. Which treatment would you suggest, and what are its risks for me?

Sources

  1. Arteriovenous Malformations. American Association of Neurological Surgeons. Published April 4, 2024. Open source
  2. Signs and Symptoms of Stroke. Centers for Disease Control and Prevention. Published May 19, 2026. Open source
  3. Arteriovenous Malformations (AVMs). National Institute of Neurological Disorders and Stroke. Published March 13, 2026. Open source
  4. Spetzler RF, Ponce FA. A 3-tier classification of cerebral arteriovenous malformations. J Neurosurg. 2011;114(3):842-849. Published October 8, 2010. Open source
  5. Gross BA, Du R. Natural history of cerebral arteriovenous malformations: a meta-analysis. J Neurosurg. 2013;118(2):437-443. Published November 30, 2012. Open source
  6. Arteriovenous malformation - cerebral. MedlinePlus Medical Encyclopedia. US National Library of Medicine. Published October 23, 2024. Open source
  7. Nugroho SW, Zaragita N, Nugroho AW, et al. A systematic review and meta-analysis of microsurgery and radiosurgery outcomes in low-grade cerebral arteriovenous malformations: obliteration rates, morbidity, and mortality. Brain Spine. 2026;6:106116. Published June 6, 2026. Open source
  8. van Beijnum J, van der Worp HB, Buis DR, et al. Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA. 2011;306(18):2011-2019. Published November 9, 2011. Open source
  9. Mohr JP, Parides MK, Stapf C, et al; ARUBA investigators. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet. 2014;383(9917):614-621. Published November 20, 2013. Open source
  10. Mohr JP, Overbey JR, Hartmann A, et al; ARUBA co-investigators. Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised controlled trial. Lancet Neurol. 2020;19(7):573-581. Published July 1, 2020. Open source
  11. Alrohimi A, Achey RL, Thompson N, et al. Treatment outcomes for ARUBA-eligible brain arteriovenous malformations: a comparison of real-world data from the NVQI-QOD AVM registry with the ARUBA trial. J Neurointerv Surg. 2024;17(e1):e1-e8. Published January 1, 2024. Open source
  12. Ogolo D, Ndukuba K, Akwada O, Nnama S, Achebe S, Ohaegbulam S. Comparative treatment outcomes of management modalities for unruptured brain arteriovenous malformations: a systematic review and meta-analysis of 6,124 patients. Neurol Res. 2026:1-16. Published October 2, 2026. Open source